✦ LIBER ✦

Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma

✍ Scribed by Agustin Avilés; María J. Nambo; Natividad Neri; Sergio Cleto; Claudia Castañeda; Judith Huerta-Guzmàn; Edgar Murillo; Margarita Contreras; Alejandra Talavera; Martha González

Book ID: 110625622
Publisher: Springer US
Year: 2007
Tongue: English
Weight: 60 KB
Volume: 24
Category: Article
ISSN: 1357-0560
DOI: 10.1007/bf02685907

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9211 Dose dense R-CHOP-14 may be superio

9211 Dose dense R-CHOP-14 may be superior to conventional R-CHOP-21 with comparable toxicities in Asian patients with high risk Diffuse Large B Cell Lymphoma

✍ Tai, W.; Tan, I.B.; Tan, M.Y.; Ngeow, Y.Y.; Koo, Y.X.; Tao, M.; Quek, R.; Lim, S 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Two-weekly dose-adjusted (DA)-EPOCH-like

Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma

✍ García-Suárez, Julio; Flores, Elena; Callejas, Marta; Arribas, Ignacio; Gil-Fern 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Pegfilgrastim as hematopoietic support f

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma

✍ Ulrich J. M. Mey; Anna Maier; Ingo G. H. Schmidt-Wolf; Carsten Ziske; Helmut For 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 136 KB

High serum vascular endothelial growth f

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

✍ Sari Riihijärvi; Heidi Nurmi; Harald Holte; Magnus Björkholm; Øystein Fluge; Lar 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

Prospective phase II study of rituximab

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

✍ Oki, Yasuhiro; Westin, Jason R.; Vega, Francisco; Chuang, Hubert; Fowler, Nathan 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB

Biweekly rituximab, cyclophosphamide, vi

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

✍ Gaetano Corazzelli; Ferdinando Frigeri; Manuela Arcamone; Anna Lucania; Maria Ro 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 290 KB